tirzepatide type 1 diabetes trial Clinical trials of subcutaneous (SURMOUNT-1, -2 and -3 Tirzepatide for diabetes: on track

Speak to your healthcare provider if: Weight concerns are significantly affecting your mood or self-esteem You are considering stopping fluoxetine due to weight changes You notice signs of disordered eating patterns Weight issues are interfering with your recovery from depression, anxiety, or bulimia Your GP can help balance the benefits of fluoxetine for your mental health against any weight-related concerns, potentially adjusting treatment or providing additional support

Slow titration helps your body adjust and reduces the risk of side effects

The AalenJohansen estimator and the FineGray sub-distribution hazard models were used to account for the competing risk of death

while the decrease on left side (Placebo treated) in Hemi-MASI was insignificant ( P value = 0.1)